SCHEMBL667261

SCHEMBL667261

Oc1c(Cl)c(I)nc2ccccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.52
MAOB P27338 1/20 0.52
KDM4E B2RXH2 5/20 0.38
ALDH1A1 P00352 4/20 0.38
TDP1 Q9NUW8 3/20 0.38
GLA P06280 3/20 0.38
DHODH Q02127 2/20 0.38
HPGD P15428 2/20 0.38
CASP1 P29466 2/20 0.38
CASP7 P55210 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HSD17B10 Q99714 2/20 0.38
PDE10A Q9Y233 1/20 0.38
CHRM2 P08172 1/20 0.38
ADRA2A P08913 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
CHRM1 P11229 1/20 0.38
NQO2 P16083 1/20 0.38
DRD1 P21728 1/20 0.38
ACHE P22303 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3665178 0.80 DHODH (0.43) MAOAMAOBKDM4EALDH1A1TDP1
SCHEMBL8521020 0.80 MAOA (0.56) MAOAMAOBKDM4EALDH1A1TDP1
SCHEMBL10527277 0.77 MAOA (0.47) MAOAMAOBKDM4EALDH1A1TDP1
SCHEMBL5388884 0.74 ALDH1A1 (0.57) MAOAMAOBKDM4EALDH1A1DHODH
Acridone SCHEMBL243819 0.74 KDM4E (0.56) MAOAMAOBKDM4EALDH1A1TDP1
SCHEMBL10527280 0.73 MAOA (0.57) MAOAMAOBKDM4EALDH1A1TDP1
SCHEMBL1758027 0.73 MAOA (0.57) MAOAMAOBKDM4EALDH1A1TDP1
SCHEMBL525342 0.73 MAOA (0.52) MAOAMAOBKDM4EALDH1A1TDP1
Acridone SCHEMBL5719993 0.72 KDM4E (0.54) MAOAMAOBKDM4EALDH1A1TDP1
Acridone SCHEMBL345058 0.72 ALDH1A1 (0.54) MAOAMAOBKDM4EALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102274347-A Anticancer composition and application thereof 2011-12-14 CN claimed
US-4485091-A HYDROGEN PEROXIDE, OIL IN WATER EMULSION QUINODERM LIMITED (GB) 1984-11-27 US claimed
US-20230405025-A1 CANNABINOID-CONTAINING COMPOSITIONS AND USE FOR TREATING AND PREVENTING DISEASES Max Biology Co. Ltd. (KH) 2023-12-21 US disclosed
EP-4225298-A1 CANNABINOID-CONTAINING COMPOSITIONS AND USE FOR TREATING AND PREVENTING DISEASES MAX BIOLOGY CO. LTD. (KH) 2023-08-16 EP disclosed
US-20200345806-A1 METHOD AND COMPOSITION FOR SYNCHRONIZING TIME OF INSEMINATON UNITED AH II LLC (US) 2020-11-05 US disclosed
US-10668127-B2 Method and composition for synchronizing time of insemination UNITED-AH II, LLC (US) 2020-06-02 US disclosed
EP-2925339-B1 METHOD FOR SYNCHRONIZING TIME OF INSEMINATION IN GILTS UNITED AH II LLC (US) 2020-04-29 EP disclosed
US-10376558-B2 Method and compositions for synchronizing time of insemination in gilts UNITED-AH II, LLC (US) 2019-08-13 US disclosed
US-10286031-B2 Method of manufacture of GnRH-containing gel UNITED-AH II, LLC (US) 2019-05-14 US disclosed
EP-3131567-B1 METHOD OF MANUFACTURE OF GNRH-CONTAINING GEL UNITED AH II LLC (US) 2019-04-10 EP disclosed
US-20180133283-A1 METHOD AND COMPOSITIONS FOR SYNCHRONIZING TIME OF INSEMINATION IN GILTS JBS UNITED ANIMAL HEALTH II LLC (US) 2018-05-17 US disclosed
US-5840744-A Intravaginal treatment of vaginal infections with buffered metronidazole compositions MINNESOTA MINING AND MANUFACTURING CO. (US) 1998-11-24 US disclosed
US-5536743-A Intravaginal treatment of vaginal infections with buffered metronidazole compositions CURATEK PHARMACEUTICALS LIMITED PARTNERSHIP (US) 1996-07-16 US disclosed
EP-0404376-B1 Buffered metronidazole compositions for intravaginal treatment of vaginal infections CURATEK PHARMACEUTICALS (US) 1994-03-23 EP disclosed
EP-0404376-A2 Buffered metronidazole compositions for intravaginal treatment of vaginal infections CURATEK PHARMACEUTICALS Limited Partnership (US) 1990-12-27 EP disclosed
WO-1990014832-A1 IMPROVED INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS CURATEK PHARMACEUTICALS LIMITED PARTNERSHIP (US) 1990-12-13 WO disclosed
US-4668517-A GASTROINTESTINAL DISORDERS, DIARRHEA NORWICH EATON PHARMACEUTICALS, INC. (US) 1987-05-26 US disclosed
EP-0137212-A2 Ointment bases and ointments OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1985-04-17 EP disclosed
US-4485091-A HYDROGEN PEROXIDE, OIL IN WATER EMULSION QUINODERM LIMITED (GB) 1984-11-27 US disclosed
US-4017615-A ESPECIALLY USEFUL FOR ANTIINFLAMMATORY TOPICAL CORTICOIDS SYNTEX CORPORATION (PM) 1977-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10286031-B2 Method of manufacture of GnRH-containing gel GNRHR, SHBG, LPXN MAOA 911/4885MAOB 1111/4885KDM4E 1275/4885
US-10376558-B2 Method and compositions for synchronizing time of insemination in gilts GNRHR, LHCGR, PIGS MAOA 3739/4885MAOB 3615/4885KDM4E 4723/4885
US-20180133283-A1 METHOD AND COMPOSITIONS FOR SYNCHRONIZING TIME OF INSEMINATION IN GILTS GNRHR, LHCGR, PIGS MAOA 3739/4885MAOB 3615/4885KDM4E 4723/4885
US-20230405025-A1 CANNABINOID-CONTAINING COMPOSITIONS AND USE FOR TREATING AND PREVENTING DISEASES CNR2, CNR1, FAAH MAOA 3306/4885MAOB 3685/4885KDM4E 1565/4885
US-20200345806-A1 METHOD AND COMPOSITION FOR SYNCHRONIZING TIME OF INSEMINATON SHBG, PIGS, NR5A1 MAOA 2958/4885MAOB 2174/4885KDM4E 4834/4885
US-10668127-B2 Method and composition for synchronizing time of insemination SHBG, PIGS, NR5A1 MAOA 2792/4885MAOB 2932/4885KDM4E 4780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.